Caxton Associates LP Halozyme Therapeutics, Inc. Transaction History
Caxton Associates LP
- $2.65 Billion
- Q3 2024
A detailed history of Caxton Associates LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Caxton Associates LP holds 34,432 shares of HALO stock, worth $1.64 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
34,432
Previous 25,432
35.39%
Holding current value
$1.64 Million
Previous $1.33 Million
47.93%
% of portfolio
0.07%
Previous 0.05%
Shares
11 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$838 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$613 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$315 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$193 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$162 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.62B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...